Clinical Study
High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases
Table 2
Predicted duration of survival versus actual duration of survival (by DS-GPA score).
| Patient | DS-GPA | Predicted median duration of survival based on DS-GPA (months) | Duration of survival from HD IL-2 initiation (months) | Duration of survival from diagnosis of brain metastases (months) |
| 8 | 1 | 3.38 | 3.0 | 4.7 |
| 1 | 2 | 4.7 | 6.7 | 7.4 | 4 | 2 | 4.7 | 13.3 | 15.2 | 5 | 2 | 4.7 | 18.2 | 19.6 | 6 | 2 | 4.7 | 5.3 | 5.4 |
| 2 | 3 | 8.77 | 10.6 | 13.5 | 7 | 3 | 8.77 | 2.1 | 5.1 |
| 3 | 4 | 13.2 | 19.0 | 23.7 |
|
|